蚓激酶治疗心肌梗死合并高纤维蛋白原血症43例疗效观察

首都医科大学学报 ›› 1999, Vol. 20 ›› Issue (4): 264-265.

蚓激酶治疗心肌梗死合并高纤维蛋白原血症43例疗效观察

高颖, 秦明照

首都医科大学附属北京同仁医院心内科

收稿日期:1999-01-18 修回日期:1900-01-01 出版日期:1999-10-15 发布日期:1999-10-15

Lumbrokinasein Treatmentof Patients with Hyperfibrinogenemia ofCoronary Atherogenesis Disease

Gao Ying, Qin Mingzhao

Dept. of Cardiology, Beijing Tongren Hospital, Affiliate of Capital University of Medical Sciences

Received:1999-01-18 Revised:1900-01-01 Online:1999-10-15 Published:1999-10-15

摘要/Abstract

摘要： 用蚓激酶治疗心肌梗死合并高纤维蛋白原血症43例,分别于用药前、用药后测定血纤维蛋白原。发现用蚓激酶2周后,血纤维蛋白原质量浓度明显下降〔(4.33±1.09)g/L〕,与用药前〔(5.34±0.89)g/L〕相比有显着性差异(P<0.05).用药3周后纤维蛋白原进一步降低〔(3.71±0.48)g/L〕,与用药前和用药后2周相比均有显着性差异(均P<0.05).用药后2周和3周,蚓激酶组与对照组相比亦有显着性差异(均P<0.05),且无明显不良反应。结果提示蚓激酶治疗高纤维蛋白原血症有一定疗效,可以考虑做为冠心病的预防用药。

关键词: 冠心病, 高纤维蛋白原血症, 蚓激酶胶囊

Abstract: The aim of this study is to evaluate the effects of lumbrokinase on hyperfibrinogenemia.Patients with hyperfibrinogenemia were orally ad ministered lum brokinase six tablets per day for three weeks.Seru m fibrinogen level was examined before and after treatment. Compared with the control groups which were given antilipemia or (and) antiplatelet aggregation drugs, serum fibrinogen inlumbrokinase treated group significantly decreased two weeks after treatment in a time related manner 〔Before treatment (5.34 ±0.89) g/L,two weeks aftertreatment (4.33 ±1.09) g/L,three weeks after treatment (3.71 ±0.48) g/L〕. These results showed that lumbrokinase could relieve hyperfibrinogenemia,therefore the formation of thrombi would be decreased.Lum brokinase which had less side effects could be considered as a preventive drug of coronary atherogenesis disease.

Key words: coronary atherogenesis disease (CAD), hyperfibrinogenemia, lu mbrokinase capsule

中图分类号:

R541.4

高颖;秦明照. 蚓激酶治疗心肌梗死合并高纤维蛋白原血症43例疗效观察[J]. 首都医科大学学报, 1999, 20(4): 264-265.

Gao Ying;Qin Mingzhao. Lumbrokinasein Treatmentof Patients with Hyperfibrinogenemia ofCoronary Atherogenesis Disease[J]. Journal of Capital Medical University, 1999, 20(4): 264-265.

[1]	苏云娟, 王京京, 韩晓涛, 刘海燕, 陈永福, 杨柳, 吴其明. 青年男性冠心病的危险因素及Framingham风险评分的预测价值[J]. 首都医科大学学报, 2022, 43(1): 143-148.
[2]	谷珊珊, 王蒨, 董薇, 焦建, 苏航, 付瑛. 心脏融合显像定量评价功能相关冠状动脉狭窄的临床研究[J]. 首都医科大学学报, 2013, 34(1): 36-42.
[3]	南楠;金泽宁;杨泽. 脂联素基因多态性与2型糖尿病合并冠心病的关联研究[J]. 首都医科大学学报, 2012, 33(4): 421-426.
[4]	高敬;华琦;王彩荣;李晓辉;高承梅. 实时三维超声心动图评价冠心病患者左心功能[J]. 首都医科大学学报, 2008, 29(4): 487-489.
[5]	王珊;谭静;华琦. 辛伐他汀对稳定性冠心病患者的血清高敏C-反应蛋白水平的影响[J]. 首都医科大学学报, 2008, 29(4): 490-492.
[6]	陈可冀;薛梅;殷惠军. 血小板活化与冠状动脉粥样硬化性心脏病和血瘀证的关系[J]. 首都医科大学学报, 2008, 29(3): 266-269.
[7]	杨毅;袁申元;潘素芳;钱宁. 体质量指数与糖尿病、冠心病、脑卒中发病率的相关性[J]. 首都医科大学学报, 2006, 27(5): 669-671.
[8]	赵秀丽;周延明;杨金奎;李金城;张慧;吴莹;张仁汉;胡大一. 格列吡嗪控释片治疗冠心病合并2型糖尿病的临床研究[J]. 首都医科大学学报, 2006, 27(1): 78-80.
[9]	陈欣;杨明;邹凤军;丁五麟;张小航;王青;高亢;潘国忠;尹朝霞;韩凌;胡文泽;岑强. 腺苷超声心动图负荷试验诊断冠心病的应用价值[J]. 首都医科大学学报, 2005, 26(2): 136-139.
[10]	张雪莲;傅汉菁;潘素芳. 糖尿病慢性大血管并发症与vWF的关系[J]. 首都医科大学学报, 2004, 25(4): 488-492.
[11]	王旭东;樊峥;傅研;殷红;翟艳玲;祁雅慧;朱宇清;王瑾;赵相印. 2型糖尿病合并冠心病患者纤溶酶原激动抑制剂-1基因多态性分析[J]. 首都医科大学学报, 2004, 25(2): 223-226.
[12]	王青;胡大一;王杰平;尹朝霞. 糖化低密度脂蛋白与冠心病相关性的研究[J]. 首都医科大学学报, 2003, 24(1): 47-50.
[13]	傅研;王旭东;翟艳玲;樊峥;杨玲;朱宇清;祁雅慧;赵相印. 纤溶酶原激动抑制剂-1基因4G/5G多态性与冠心病[J]. 首都医科大学学报, 2001, 22(2): 119-122.
[14]	徐晓薇;杜凤和;张春玲. 叶酸治疗高半胱氨酸血症30例临床观察[J]. 首都医科大学学报, 2001, 22(1): 48-49.
[15]	屈正;张兆光;于建波;叶建光;孙衍庆;马临安;徐屹. 高龄高危患者激光心肌血运重建术[J]. 首都医科大学学报, 2000, 21(3): 198-200.